The trial is taking place at:

Asan Medical Center | Clinical Trial Center

Veeva-enabled site

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers



Status and phase

Active, not recruiting
Phase 1


HER2-expressing Cancers


Drug: ZW49

Study type


Funder types




Details and patient eligibility


This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers.

Full description

The study will use a 3+3 dose-escalation study design to evaluate the safety and tolerability of ZW49 and to determine the MTD or RD of ZW49 for further study. Selected expansion cohorts will be subsequently opened based upon Safety Monitoring Committee (SMC) recommendation and sponsor approval to further evaluate the safety and tolerability of ZW49 at the MTD or RD and to assess preliminary anti-tumor activity.


174 estimated patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • Pathologically-confirmed diagnosis of breast cancer, gastroesophageal adenocarcinoma (GEA), or other HER2-expressing cancer with evidence of locally advanced (unresectable) and/or metastatic disease.

    • Dose-escalation (Cohort 1): HER2-high advanced solid tumors
    • Expansion (Cohort 2): HER2-high breast cancer
    • Expansion (Cohort 3): HER2-high GEA
    • Expansion (Cohort 4): HER2-high other non-breast and non-GEA cancers
  • Progressive disease that has progressed on or been refractory to all standard of care. Patients who were intolerant to or ineligible for standard therapy may be eligible if the reasons are carefully documented and approval is provided by the sponsor medical monitor

    • Patients with HER2-high breast cancer must have received prior treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1)
    • Patients with HER2-high GEA must have received prior treatment with trastuzumab
  • Sites of disease assessible per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    • Dose-escalation: measurable or non-measurable disease
    • Expansion: measurable disease
  • ECOG performance status score of 0 or 1

  • Adequate organ function

  • Adequate cardiac left ventricular function, as defined by a LVEF >/= institutional standard of normal

Exclusion criteria

  • History of myocardial infarction or unstable angina within 6 months prior to enrollment, troponin levels consistent with myocardial infarction, or clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension, or any history of symptomatic congestive heart failure (CHF)
  • Clinically significant infiltrative pulmonary disease not related to lung metastases
  • Active hepatitis B or hepatitis C infection or other known chronic liver disease
  • Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of patients with Gilbert's Syndrome, asymptomatic gall stones, liver metastases, or stable chronic liver disease per investigator assessment)
  • Known history of human immunodeficiency virus (HIV) infection
  • Brain metastases: Untreated CNS metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks of start of study treatment. Stable, treated brain metastases are allowed (defined as patients who are off steroids and anticonvulsants and are stable for at least 1 month at the time of screening).
  • Known leptomeningeal disease (LMD)

Trial design

Primary purpose




Interventional model

Parallel Assignment


None (Open label)

174 participants in 1 patient group

Experimental group
Drug: ZW49

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems